当地时间 6 月 10 日,据外媒报道,由于第二代1 型糖尿病(T1D)细胞疗法 VX-264 临床失利,福泰制药(Vertex)计划裁员 125 人。来源:Endpoints News根据罗德岛州(Rhode Island)工人福利和再培训通知(WARN)的通知,裁员生效日期为 8 月 5 日。此次裁员仅影响福泰制药员工的一小部分。截至 2024 年底,该公司共有 6100 名员工。VX-264...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.